Regulus’ microRNA wins potential $750m Sanofi deal
Regulus Therapeutics’ microRNA satellite technology has won the firm its biggest deal to date with French drugmaker Sanofi-Aventis agreeing a development accord worth up to $750m (€606m).
Archives for June 27, 2010
Gilead buys a $120m ticket for protein kinase research role
A deal to broaden Gilead’s research expertise into protein kinase biology has been finalised with the $120m acquisition of CGI Pharmaceuticals, in a deal that compliments its comprehensive selection of anti-HIV treatments.
TRL refocuses new US site on biologic drugs
Tanabe Research Labs (TRL) has revealed details of its new San Diego facility in which the revised layout of the site allows a fresh focus on antibody and biological approaches to autoimmune diseases such as diabetes and rheumatoid arthritis.